Lindsay J Caverly, MD
Assistant Professor of Pediatrics
The Department of Pediatrics
1500 E. Medical Center Drive L2221 UH South
Ann Arbor, MI 48109
[email protected]

Available to mentor
Lindsay J Caverly, MD
Clinical Assistant Professor
  • About
  • Links
  • Qualifications
  • Research Overview
  • Recent Publications
    • About

    The Caverly lab studies cystic fibrosis airway microbiome and nontube and cystic fibrosis. Dr. Caverly is a board certified Pediatric Pulmonologist at The University of Michigan Medical School.

    Links
    • Michigan Experts
    • PubMed
    • Michigan Medicine Web Profile
    • Lindsay Caverly Lab
    Qualifications
    • Fellowship
      Children's Hospital Colorado, Pediatric Pulmonary, 2013
    • Residency
      Children's Hospital Colorado, Pediatrics, 2010
    • BA
      Washington University, St Louis, 2002
    Research Overview

    lung infections in children with cystic fibrosis, with particular focus on atypical Mycobacteria

    Recent Publications See All Publications
    • Journal Article
      Genomic Analyses of Longitudinal Mycobacterium abscessus Isolates in a Multicenter Cohort Reveal Parallel Signatures of In-Host Adaptation.
      Choi J, Keen EC, Wallace MA, Fishbein S, Prusa J, Zimbric M, Mejia-Chew CR, Mehta SB, Bailey TC, Caverly LJ, Burnham C-AD, Dantas G. J Infect Dis, 2023 Aug 11; 228 (3): 321 - 331. DOI:10.1093/infdis/jiad187
      PMID: 37254795
    • Journal Article
      Airway bacterial community composition in persons with advanced cystic fibrosis lung disease.
      Thornton CS, Carmody LA, Kalikin LM, Opron K, Caverly LJ, LiPuma JJ. J Cyst Fibros, 2023 Jul; 22 (4): 623 - 629. DOI:10.1016/j.jcf.2023.01.001
      PMID: 36628831
    • Journal Article
      Uncontrolled asthma: when to step up therapy
      Caverly L, Taussig LM. Contemporary Pediatrics, 2023 Jul 1; 24 (34):
    • Journal Article
      Quantifying variation in home spirometry in people with cystic fibrosis during baseline health, and associations with clinical outcomes.
      Thornton CS, Magaret AS, Carmody LA, Kalikin LM, Simon RH, LiPuma JJ, Caverly LJ. J Cyst Fibros, 2023 May 25; DOI:10.1016/j.jcf.2023.05.011
      PMID: 37244842
    • Journal Article
      Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials.
      Mayer-Hamblett N, Ratjen F, Russell R, Donaldson SH, Riekert KA, Sawicki GS, Odem-Davis K, Young JK, Rosenbluth D, Taylor-Cousar JL, Goss CH, Retsch-Bogart G, Clancy JP, Genatossio A, O'Sullivan BP, Berlinski A, Millard SL, Omlor G, Wyatt CA, Moffett K, Nichols DP, Gifford AH, SIMPLIFY Study Group . Lancet Respir Med, 2023 Apr; 11 (4): 329 - 340. DOI:10.1016/S2213-2600(22)00434-9
      PMID: 36343646
    • Journal Article
      The Impact of Highly Effective Modulator Therapy on Cystic Fibrosis Microbiology and Inflammation.
      Caverly LJ, Riquelme SA, Hisert KB. Clin Chest Med, 2022 Dec; 43 (4): 647 - 665. DOI:10.1016/j.ccm.2022.06.007
      PMID: 36344072
    • Journal Article
      Can Identifying Pulmonary Exacerbation Phenotypes Guide New Treatment Approaches for Cystic Fibrosis?
      Caverly LJ. Ann Am Thorac Soc, 2022 Nov; 19 (11): 1799 - 1801. DOI:10.1513/AnnalsATS.202208-703ED
      PMID: 36318079
    • Journal Article
      Considerations for CF airway infection sampling and impact of CFTR modulators.
      Caverly LJ. J Cyst Fibros, 2022 Nov; 21 (6): 906 - 907. DOI:10.1016/j.jcf.2022.09.004
      PMID: 36153229